Imagine a relentless enemy, silently spreading through the brain, defying every attempt to stop it. That's the reality of glioblastoma, a particularly aggressive brain cancer. But what if the very fluid that bathes our brain cells is actually helping this enemy spread? That's the question Dr. Jennifer Munson and her team are tackling, and their groundbreaking research just received a major boost in the form of two new grants from the National Institutes of Health (NIH). These grants aim to unravel how brain fluid movement contributes to the insidious spread of glioblastoma, ultimately paving the way for more effective treatments.
Dr. Munson, a respected cancer researcher at Virginia Tech's Fralin Biomedical Research Institute at VTC, is focusing on the role of interstitial fluid – the liquid that surrounds brain cells – in the progression of this deadly disease. Both grants, funded by the National Cancer Institute, center on understanding how the movement of this fluid facilitates the invasion of glioblastoma cells into healthy brain tissue. This invasion is a major reason why the cancer often returns even after aggressive treatments like surgery and radiation. The crucial idea is that by understanding and controlling this fluid flow, we might be able to stop the cancer's spread. But here’s where it gets controversial... some researchers believe the interstitial fluid is merely a passive carrier, while Munson's work suggests it plays a more active role in tumor cell migration.
One of the grants, a substantial five-year award of $2.6 million, will delve into how fluid flow patterns change in response to treatment. Specifically, the team will investigate how focused ultrasound – a non-invasive technique that uses sound waves to target specific areas – can be used to improve drug delivery to the tumor. Focused ultrasound can temporarily open the blood-brain barrier (BBB), a protective shield that often prevents cancer drugs from reaching the tumor effectively. By understanding how fluid flow is affected by focused ultrasound, researchers hope to optimize this technique for more precise and effective drug delivery. This grant aims to determine if focused ultrasound can be leveraged to better target and distribute therapy, and how fluid flow can be used as a way to measure the effectiveness of the therapy. And this is the part most people miss... the fluid flow might actually change before the tumor shrinks, giving doctors an early warning if a treatment isn't working.
The second grant, a two-year award of $411,000, supports the development of a novel model that simulates the fluid-filled spaces surrounding blood vessels in the brain. This model will allow researchers to study how these spaces behave in both healthy brains and in the presence of cancer. Munson is teaming up with Dr. Malisa Sarntinoranont, a professor of mechanical engineering at the University of Florida, who brings expertise in advanced computational modeling. The collaboration will combine the Munson lab's expertise in fluid flow and imaging with Sarntinoranont's advanced computational modeling to develop the first whole-brain model of flow in the fluid-filled spaces around certain arteries. Their goal is to create a comprehensive map of fluid flow throughout the brain, providing crucial insights into how this flow contributes to the transport of cancer cells during tumor growth. The study will employ advanced MRI techniques to generate dynamic imaging of fluid flow in healthy brains and preclinical models with tumors. The team will generate detailed maps of fluid flow and use the maps to build computational models of flow in tumor development in the whole brain.
Why is this so important? Because glioblastoma is one of the most common and deadliest types of brain tumors in adults. Currently, there are no truly effective therapies, and the average survival rate is tragically short. As Dr. Munson puts it, "New approaches to understanding how this cancer invades tissues and recurs, and better treatments and targeted methods, are desperately needed." The model can then be used to examine differences in flow during tumor development, and to test the impacts of the anti-inflammatory and commonly administered drug dexamethasone on glioblastoma tumor progression.
Dr. Munson's previous work has already demonstrated the ability to predict where a tumor is likely to reappear after treatment. Now, by combining this predictive capability with the precision of focused ultrasound, her team is poised to make significant strides in the fight against glioblastoma. Dr. Cheng-Chia "Fred" Wu, a radiation oncologist and cancer researcher at the Fralin Biomedical Research Institute, is collaborating on the focused ultrasound aspect of the project. The labs will use mapping to identify the best focused ultrasound targets and work with Associate Professor Eli Vlaisavljevichand Research Associate Professor Adam Maxwellof Virginia Tech's Department of Biomedical Engineering and Mechanics to develop a more precise focused ultrasound system. The study also aims to determine how fluid flow is affected by different therapies. It could serve as a biomarker for therapeutic efficacy. In addition, the researchers will work with Russell Rockne, associate professor at the City of Hope comprehensive cancer care center in California, to develop mathematical models to predict tumor progression and drug distribution in light of changes.
"This coupling of precision identification with precision equipment is a major translational leap for our research," said Munson. "By the end of our project, we expect to have a tool set and understanding of how fluid flow changes and predicts therapeutic responses and progression in this devastating and treatment-resistant cancer." This research offers a beacon of hope for patients and families affected by glioblastoma.
What do you think? Could targeting fluid flow be the key to finally conquering this devastating disease? And if so, what ethical considerations should guide the development of these new therapies? Share your thoughts in the comments below!
